Report results from the PULSAR open-label extension and additional SPECTRA Phase 2 results
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- May 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Results from the open-label extension period of the PULSAR Phase 2 trial and additional results from the SPECTRA Phase 2 trial are expected in the first half of 2021.”
What we found
Evidence strength A What the grades mean
The filings show PULSAR open-label extension interim results and additional SPECTRA interim results were presented at the ATS 2021 conference in May 2021, before the June 2021 deadline.
-
A Acceleron Pharma Inc. 10-Q filed 2021-08-05
“In May 2021, we presented interim results from the ongoing 18-month open-label extension of the PULSAR trial at the ATS 2021 International Conference” ✓ confirmed on the page
-
A Acceleron Pharma Inc. 10-Q filed 2021-08-05
“we presented additional preliminary interim results at the ATS 2021 International Conference” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- PULSAR extension and SPECTRA Phase 2 results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Acceleron Pharma Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C280600-024527 · Corrections policy